title: Monocusp - novel common femoral vein monocusp surgery uncorrectable chronic venous insufficiency with aplastic/dysplastic valves.
abstract: OBJECTIVE
  Previous reparative valvular surgical options directed at reconstructing damaged common femoral vein (CFV) valves associated with pathological chronic venous insufficiency (CVI) have not succeeded in reliably managing CVI. In consequence, venous valvuloplasty is rare and most patients are managed conservatively. As a result, monocusp surgery was identified as an optional surgical solution for this large underserved patient group.
  
  
  METHODS
  Ulcer patients appear at wound clinics and often experience disappointing results. Monocusp valves were constructed utilizing viable vein wall in 14 operations on 11 patients. These patients were observed for four years to see if such an autogenous vein wall valve might control aggressive symptomatic CVI when faced with unusable valves.
  
  
  RESULTS
  Long-term follow-up showed that the monocusp valves remained competent at four years. Symptomatic failures have not appeared at this time. Pain, swelling, ulcers and leg congestion were reliably reversed. VEnous INsufficiency Epidemiologic and Economic Study (VEINES) classification (see Abenhaim L, Krux X, VIENES Study collaborators. Angiology 1997;48:59 and Kurz X, Kahn SR, Abenhaim L, et al. Int Angiol 1999;18:83-102) improved over four years from 2.7 +/- 0.9 to 0 (P < 0.001); CEAP classifications (see Kistner RL, Eklof B, Masuda EM. Mayo Clin Proc 1996;71:338-45) improved from grade 4-6 to 0-1 (CEAP is not generally a postoperative grading system, but it can be used to develop some form of qualitative analyses as to intervention effectiveness, i.e. what existed preoperatively no longer exists postoperatively. Its postsurgery use is limited by (C5) classification - history of ulcer, which by definition cannot go below that with a history of ulcer even if the ulcer has been cured). Mean venous reflux scores decreased from 3.8 +/- 0.4 to 0.3 +/- 0.5 (P < 0.001).
  
  
  CONCLUSIONS
  Monocusp implantation reliably resolved patient symptoms when unusable CFV valves were encountered. Postoperative CFV reflux is usually undetectable. The monocusp valve exhibits minimal thrombogenicity related to its viability with attendant antithrombotic hormone production capacity and has markedly improved the patient's quality of life. Full thickness monocusp surgery could become widespread with the difficult dysplastic/aplastic CVI patient subset because of its simplicity, repeatability, durability, low complication rate, effectiveness, persistent availability and viability providing nitric oxide synthase and thymomodulin hormone production capacity. The full thickness of vein wall has distinct advantages over other partial thickness valve creation methods because of its long-term vitality. Postoperative coumadin is recommended for six months to minimize risks of deep vein thrombosis and/or pulmonary embolism.
authors.affiliation: Scottsdale Healthcare, AZ, USA. jopiemd@aol.com
authors.forename: J C
authors.initials: JC
authors.lastname: Opie
authors.forename: T
authors.initials: T
authors.lastname: Izdebski
authors.forename: D N
authors.initials: DN
authors.lastname: Payne
authors.forename: S R
authors.initials: SR
authors.lastname: Opie
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D002908:Chronic Disease; D005240:Feasibility Studies; D005268:Femoral Vein / Q000000981:diagnostic imaging / Q000601:surgery*; D006801:Humans; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control; D011788:Quality of Life; D012720:Severity of Illness Index; D013524:Surgical Flaps; D013536:Suture Techniques; D013997:Time Factors; D016896:Treatment Outcome; D018616:Ultrasonography, Doppler, Duplex; D014656:Vascular Surgical Procedures / Q000009:adverse effects; D014689:Venous Insufficiency / Q000000981:diagnostic imaging / Q000601:surgery*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin